Company announcement no. 04-2025
Frederiksberg, 2025.03.31
Monsenso A/S announced today that the Company´s share capital had been increased by nominally DKK 13,332.00 due to the exercise of warrant programs.
The capital increase is subscribed in cash at a price per share of DKK 0.22, without pre-emptive rights for the company's existing shareholders or others. Proceeds for the company amount to DKK 29,330.00. The capital increase corresponds to 0.20 % of the company's previous share capital.
The new shares are ordinary, without special rights and freely transferable negotiable instruments. The new shares are entitled to dividends and other rights in the company from the time of registration of the capital increase. The new shares will be admitted to listing on Nasdaq First North Growth Market Denmark as soon as possible after registration with the Danish Business Authority.
Monsenso's current share capital amounts to a nominal DKK 6,664,018.20 divided into 66,640,182 shares of DKK 0.10. The capital increase is expected to be completed soon, and after registration the following is expected:
Nominal value of shares DKK | 6,677,350.20 |
The volume of shares (nom. DKK 0.10) | 66,773,502 |
Any inquiries regarding this notice should be directed to:
Monsenso
CEO
Thomas Lethenborg
Tel +45 21 29 88 27
E-mail: lethenborg@monsenso.com
Chairman of the board
Peter Mørch Eriksen
E-mail: eriksen@monsenso.com
Certified Adviser:
HC Andersen Capital
Bredgade 23,
1260 København K
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com